✦ LIBER ✦

Multiple-dose pharmacokinetics of the new H1-receptor antagonist tazifylline in healthy volunteers

✍ Scribed by R. Bruno; I. Jullien; J. Auger; A. Iliadis; R. Dow; J. McEwen; J. P. Cano; H. Pinhas

Publisher: John Wiley and Sons
Year: 1989
Tongue: English
Weight: 221 KB
Volume: 10
Category: Article
ISSN: 0142-2782
DOI: 10.1002/bdd.2510100113

No coin nor oath required. For personal study only.

✦ Synopsis

The multiple-dose pharmacokinetics of the new HI-receptor antagonist, tazifylline, were investigated in healthy volunteers. From single-dose data, tazifylline appeared to be rapidly absorbed (median tm, of 0.6 h) and eliminated (t% 1.0 f 0.2 h). However, plasma levels measured on days 3 and 8 of the multiple-dose regimen (10 mg b.i.d. for 8 days) indicated moderate accumulation. A two-compartment model best described multipledose data with a terminal half-life of 15.6 f 7.6 h consistent with twicedaily dosing of tazifylline.

📜 SIMILAR VOLUMES

Multiple dose pharmacokinetics of caffei

Multiple dose pharmacokinetics of caffeine administered in chewing gum to normal healthy volunteers

✍ Shariq A. Syed; Gary H. Kamimori; William Kelly; Natalie D. Eddington 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB 👁 1 views

The purpose of this study was to examine the pharmacokinetics of three doses of caffeine administered as Stay Alert chewing gum in a multiple dose regimen. ## Methods: A double-blind, parallel randomized, four-treatment study design was employed. the treatment groups were: 50, 100 and 200 mg caffe

Single dose pharmacokinetics of HEPP, a

Single dose pharmacokinetics of HEPP, a new anticonvulsant in normal healthy volunteers

✍ Dinora F. González-Esquivel; Francisco Rubio-Donnadieu; Guillermo Carvajal S.; H 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 2 views

The pharmacokinetics and the dose proportionality of a new anticonvulsant compound, HEPP (D,L-3-hydroxy-3-ethyl-3-phenylpropionamide) was studied in healthy male volunteers as part of the pharmacological evaluation for new drugs. Study was performed administering doses of 250, 375, 500 and 625 mg of

The single dose pharmacokinetics and saf

The single dose pharmacokinetics and safety of deramciclane in healthy male volunteers

✍ Harri Kanerva; Olavi Kilkku; Esa Heinonen; Antti Helminen; Juha Rouru; Simo Tarp 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 201 KB 👁 2 views

The pharmacokinetics and tolerability of a new putative non-benzodiazepine type anxiolytic compound deramciclane was studied in two consecutive studies. An open dose-escalation design was used to study doses from 0.2 to 50 mg in 18 healthy male volunteers. In the second study doses from 50 to 150 mg

Dose-proportional pharmacokinetics of a

Dose-proportional pharmacokinetics of a new 5-lipoxygenase inhibitor, ABT-761, in healthy volunteers

✍ Shekman L. Wong; Jeffrey Drajesk; Min S. Chang; Galen Witt; Walid M. Awni 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB 👁 2 views

, a new potent 5-lipoxygenase inhibitor, is under development for the treatment of asthma. The pharmacokinetics and dose proportionality of ABT-761 after single doses (10 -160 mg) of ABT-761 in 24 healthy male volunteers were investigated in a double-blind, placebo-controlled study. The compound was

Single- and multiple-dose pharmacokineti

Single- and multiple-dose pharmacokinetics of oral dolasetron and its active metabolites in healthy volunteers: part 2

✍ Dan C. Dimmitt; Youn Sung Choo; Lorene A. Martin; Thangam Arumugham; William F. 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB 👁 2 views

The single-and multiple-dose pharmacokinetics and dose-proportionality of oral dolasetron and its active metabolites over the therapeutic dose range was investigated in 18 healthy men. In an open-label, randomized, complete three-way crossover design, each subject received three separate doses: 50,

Dose proportionality and comparison of s

Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16 455) and its enantiomers in healthy male volunteers

✍ Doris K. Robbins; Mark A. Castles; David J. Pack; Vijay O. Bhargava; Scott J. We 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 225 KB 👁 2 views

The pharmacokinetics and dose proportionality of fexofenadine, a new non-sedating antihistamine, and its enantiomers were characterized after single and multiple-dose administration of its hydrochloride salt. A total of 24 healthy male volunteers (31 98 years) received oral doses of 20, 60, 120 and